[GILD] Gilead Sciences Thesis 2026: Yeztugo HIV PrEP Launch Tests Post-Biktarvy Growth Replacement

Key Takeaways

Gilead Sciences Inc.'s fiscal year 2025 (calendar year ended December 31, 2025) was the year that defined the strategic transition for the focused HIV-driven pharmaceutical company through the commercial launch of lenacapavir for HIV pre-exposure prophylaxis (PrEP — branded Yeztugo, FDA approved June 2024 as a twice-yearly subcutaneous injection that represents the most significant innovation in HIV prevention in over a decade): revenue of approximately $28-30B (+~3-5% YoY), adjusted operating margin of approximately 36% generating operating income of approximately $10-10.5B, and adjusted EPS of approximately $7.10-7.40 on approximately 1.25B diluted shares. The strategic identity that distinguishes Gilead from peer pharmaceutical companies (Pfizer covered separately on post-COVID + Seagen integration, Merck on Keytruda dominance, Eli Lilly on GLP-1 transformation, Bristol-Myers Squibb, AbbVie) is the deliberate concentration in HIV — Gilead's HIV franchise generates approximately 60% of revenue ($18B FY2025) and dominates the global HIV treatment market with Biktarvy (single-tablet HIV regimen, the dominant HIV treatment globally with approximately $13B annual revenue). The investment thesis for Gilead in FY2026 centers on three structural questions: (1) whether lenacapavir for HIV PrEP (Yeztugo) commercial launch ramps as projected — the twice-yearly injectable HIV prevention drug represents a fundamentally novel modality that competes with daily oral PrEP (Truvada generics, Descovy) plus the cabotegravir-based Apretude bimonthly injection (ViiV Healthcare/GSK partnership) — and whether lenacapavir captures meaningful share of the approximately 380K US PrEP user population plus expansion into international markets; (2) whether the Oncology franchise (Trodelvy antibody-drug conjugate for triple-negative breast cancer, Yescarta and Tecartus CAR-T cell therapies for hematologic cancers) sustains the multi-product growth thesis that Gilead has positioned as the post-HIV diversification strategy; and (3) whether the selected pipeline assets (lenacapavir for HIV treatment, magrolimab for hematologic cancers, plus emerging earlier-stage assets) provide the post-Biktarvy LOE growth replacement (Biktarvy patent expires 2033 but generic challenge could materialize earlier).

---

Gilead Sciences was founded in 1987 in Foster City, California by Michael Riordan to commercialize antiviral therapeutics, evolving over 38 years through landmark drug development achievements that defined the modern HIV treatment paradigm: Viread (tenofovir disoproxil fumarate, approved 2001) established Gilead as the leader in HIV nucleoside reverse transcriptase inhibitors; Atripla (combination tenofovir/emtricitabine/efavirenz, approved 2006) was the first single-tablet HIV regimen; Stribild, Complera, Truvada, Genvoya, Odefsey, Descovy, Biktarvy, plus Sunlenca/Yeztugo (lenacapavir) progressively defined the standard of HIV care globally. Strategic acquisitions through the 2010s and 2020s expanded beyond HIV: Pharmasset (2011, $11.2B for sofosbuvir HCV treatment that became Sovaldi/Harvoni — the breakthrough HCV cure that transformed Gilead but also created the post-HCV revenue cliff as cure rates exceeded 90% and treated patient population reduced rapidly), Kite Pharma (2017, $11.9B for CAR-T cell therapy capability — Yescarta), Forty Seven (2020, $4.9B for magrolimab CD47 antibody), Immunomedics (2020, $21B for sacituzumab govitecan/Trodelvy in triple-negative breast cancer), MyoKardia (2020, divested in 2021 for $13.1B to Bristol-Myers Squibb). CEO Daniel O'Day, who has led Gilead since March 2019 (succeeding John Milligan), oversees the strategic positioning that emphasizes HIV franchise stewardship plus diversification into oncology and selected emerging modalities.

Business Structure

Gilead reports through therapeutic area categories rather than formal business segments.

HIV (~$18B revenue, ~60% of total): The dominant therapeutic area. Major franchises:

• Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) (~$13B revenue): The single-tablet HIV regimen that has been the dominant HIV treatment globally since launch 2018. Biktarvy is approved as initial HIV treatment plus virologically suppressed switch indication. Patent expiration 2033 in major markets, but oral patents may face challenges earlier.
• Descovy (emtricitabine/tenofovir alafenamide) (~$2B): For HIV PrEP plus selected HIV treatment combinations.
• Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) (~$1B): Legacy single-tablet regimen, declining as patients transition to Biktarvy.
• Sunlenca/Yeztugo (lenacapavir) (~$0.5-1B FY2025 launch year — significant growth potential): The capsid inhibitor — first-in-class mechanism — approved for treatment of multi-drug-resistant HIV (Sunlenca FDA approved 2022) plus PrEP (Yeztugo FDA approved June 2024). Twice-yearly subcutaneous injection administration represents transformative dosing convenience.
• Other HIV (~$1B): Truvada (post-LOE generic competition limited revenue), Atripla (declining legacy), Stribild (declining).

Oncology (~$3.5-4B revenue, ~12% of total): The diversified cancer franchise. Sub-segments:

• Trodelvy (sacituzumab govitecan) (~$1.5B): Antibody-drug conjugate for triple-negative breast cancer (TNBC), HR+ HER2- breast cancer, urothelial cancer (selected indications). Trodelvy is the leading TROP2-targeted ADC, competing with Daiichi-Sankyo's Datroway (datopotamab deruxtecan, FDA approved late 2024).
• Yescarta (axicabtagene ciloleucel) + Tecartus (brexucabtagene autoleucel) (~$1.5-2B): CAR-T cell therapies — Yescarta for diffuse large B-cell lymphoma (DLBCL) plus selected indications including 2L+ DLBCL post the ZUMA-7 trial expansion; Tecartus for mantle cell lymphoma plus B-cell ALL.
• Other Oncology: Selected smaller pipeline assets, magrolimab in development for hematologic cancers (multiple Phase 3 trials).

Liver Disease (~$2.5B revenue, ~8% of total): The legacy HCV franchise plus selected hepatitis B (HBV) products. HCV revenue continues declining as patient population treated and cured (Sovaldi, Harvoni, Epclusa, Vosevi cumulative cure rates exceeded 90% across major markets). HBV products plus emerging NASH (now MASH) selective programs.

COVID-19 (Veklury/remdesivir) (~$1B revenue, declining ~3% of total): The COVID-19 antiviral that was approved for emergency use during the pandemic. Veklury revenue declining from peak of approximately $5.6B FY2021 to approximately $1B FY2025 as COVID-19 hospitalization rates normalize.

Cell Therapy + Inflammation + Other (~$2-3B revenue): Selected smaller franchises including selected cell therapy programs beyond Yescarta/Tecartus, plus emerging inflammation programs.

Key Core Metrics Performance

Revenue, Margin, and EPS Trajectory (FY2021–FY2025)

The pattern of revenue stability around $27-30B combined with operating margin compression from approximately 46% in FY2021 to approximately 36% in FY2025 reflects multiple factors: HCV revenue continued decline (from ~$2B FY2021 to ~$1.5B FY2025), Veklury COVID revenue compression (peak $5.6B → ~$1B FY2025), plus the operating cost growth from oncology platform investments (Yescarta/Tecartus + Trodelvy + emerging pipeline) that have not yet reached full scale economics.

Lenacapavir/Yeztugo HIV PrEP Launch

The lenacapavir for PrEP launch (Yeztugo) represents Gilead's most significant HIV product launch in the past decade. The strategic value: lenacapavir's twice-yearly subcutaneous injection administration provides transformative dosing convenience versus daily oral PrEP (Truvada generics, Descovy) plus the cabotegravir-based Apretude (ViiV Healthcare/GSK) bimonthly injection. Each lenacapavir injection costs approximately $30,000 ($60,000 annual), supporting substantial revenue per patient. The US PrEP user population is approximately 380,000-450,000 with growth potential to approximately 1.5M+ as awareness expands.

HIV Franchise Concentration Risk

Biktarvy concentration at approximately 71% of HIV revenue (and approximately 45% of total Gilead revenue) represents the structural concentration risk — Biktarvy patent expiration in 2033 creates a multi-year LOE cliff that requires post-Biktarvy growth replacement.

Market Evaluation

Gilead Sciences trades at approximately 11-15x forward adjusted EPS — value-leaning multiples that reflect both the dividend yield (~3-4%) and the structural concerns about HIV concentration risk plus the post-HCV revenue compression that defined FY2018-FY2023. The bull case is lenacapavir scaling + Oncology growth + selective pipeline contribution: if Yeztugo lenacapavir for PrEP commercial launch ramps toward $3-5B by FY2027 (significant US PrEP share + international expansion + selected adjacent indications including HIV treatment combinations), if Trodelvy + Yescarta + Tecartus collectively grow toward $5-6B by FY2027, and if selected pipeline assets contribute incremental revenue, total revenue could approach $32-34B with adj. EPS approaching $7.80-8.40 by FY2027 — supporting equity at sustained 12-15x with continued dividend growth. The bear case is Biktarvy LOE concerns + Yeztugo commercial disappointment + Oncology execution issues: if generic challenges accelerate Biktarvy revenue erosion before 2033 patent expiration, if Yeztugo launch ramps slower than projected (physician adoption resistance, payer coverage challenges, alternative competitor success), or if Oncology pipeline assets fail to scale meaningfully, EPS growth could remain flat-to-negative with multiple compression risk.

The Lenacapavir/Yeztugo Strategic Position and HIV Prevention Market Transformation

The strategic argument that frames Gilead's contemporary investment thesis rests substantially on lenacapavir — Gilead's first-in-class capsid inhibitor that represents the most significant HIV prevention innovation since the original Truvada PrEP indication received FDA approval in 2012. The strategic positioning combines clinical innovation (twice-yearly subcutaneous injection administration provides transformative dosing convenience versus daily oral PrEP that has historically been limited by adherence challenges) with commercial execution (Gilead's existing HIV franchise commercial infrastructure plus dedicated PrEP physician outreach team).

The lenacapavir clinical evidence: the PURPOSE-1 trial in cisgender women in sub-Saharan Africa demonstrated 100% efficacy in HIV prevention (no breakthrough infections in approximately 2,134 participants over the trial period), plus the PURPOSE-2 trial in cisgender men who have sex with men plus transgender populations demonstrated approximately 96% efficacy versus oral PrEP. These results represent the most efficacious HIV prevention data ever reported in clinical trials, establishing lenacapavir as the gold standard of HIV prevention efficacy.

The commercial trajectory: lenacapavir for HIV PrEP (Yeztugo) launched June 2024 with FDA approval; the Q3 2024 launch was constrained by limited initial commercial infrastructure plus the multi-quarter ramp typical of injectable HIV products requiring physician training and patient initiation. The FY2025 commercial ramp has been faster than initial expectations, with cumulative patients approaching 75,000-100,000 by year-end. The FY2026-FY2027 commercial trajectory depends on multiple factors: physician adoption pace (HIV-specialized physicians in the US plus selected primary care expansion), payer coverage outcomes (Medicaid coverage essential for low-income populations, commercial insurance coverage variable, Medicare coverage emerging), patient education and initiation (the twice-yearly injection requires office visits that some patients may resist versus daily oral pill), plus international market expansion (lenacapavir has been licensed at favorable pricing for low- and middle-income countries through generic licensing partnerships).

The competitive context: ViiV Healthcare (the GSK + Pfizer + Shionogi joint venture focused on HIV) markets Apretude (cabotegravir extended-release injectable for PrEP, dosed bimonthly), which has been on the market since 2021 but achieved limited commercial scale due to dosing schedule challenges. Lenacapavir's twice-yearly schedule (versus Apretude's every-two-months) plus the higher efficacy evidence supports lenacapavir's commercial advantages, but ViiV continues to have substantial HIV franchise infrastructure (Tivicay/Triumeq HIV treatment franchise) that supports Apretude commercial promotion.